Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SGC-CLK-1 is an inhibitor of CDC-like kinase 1 (Clk1) and Clk2 (IC50s = 13 and 4 nM, respectively).1 It is selective for Clk1 and Clk2 over Clk3, Clk4, homeodomain-interacting protein kinase 1 (HIPK1), HIPK2, and serine/threonine kinase 16 (STK16; IC50s = 363, 46, 50, 42, and 49 nM, respectively). SGC-CLK-1 (1 µM) inhibits the proliferation of MDA-MB-435 breast cancer and U-118 MG glioma cells. It induces diffuse localization of Clk2 and phosphorylated serine/arginine-rich (pSR) proteins, targets of Clks, without reducing the levels of phosphorylated SR proteins in MDA-MB-435 and U-118 MG cells when used at a concentration of 500 nM. See the Structural Genomics Consortium (SGC) website for more information.
WARNING This product is not for human or veterinary use.
1. SGC-